Zimmer Biomet: Recent Advancements in Robotic & Surgical Technology Look Promising! 

Zimmer Biomet’s first-quarter performance for 2025 showcased gradual growth, amidst an environment of various challenges and strategic changes. The company reported a 2.3% increase in constant currency sales, despite having one less selling day in the quarter. This growth was largely driven by specific improvements in U.S. Hips sales, which saw an almost 4% increase, and mid-single-digit growth in their S.E.T. segment. The robust U.S. Hips performance was attributed to innovations like the Z1 hip stem, HAMMR impactor, and OrthoGrid AI systems, revealing a shift where about half of the users were drawn from competitive accounts.